20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
May 2018 in “Dermatologic Surgery” August 2025 in “Skin Appendage Disorders” TCM is an effective and safe treatment for primary cicatricial alopecias.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”
March 2024 in “Clinical, cosmetic and investigational dermatology” Upadacitinib may effectively treat alopecia areata without side effects.
5 citations
,
August 1999 in “Disease-a-month” Hormonal imbalances can cause acne, and treatments may include hormone-blocking medications.
5 citations
,
July 2024 in “Archives of Dermatological Research”
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
September 1988 in “Inpharma (Balgowlah)” Retinoids are effective for acne but can cause serious side effects.
January 1988 in “Inpharma (Balgowlah)” New retinoids are effective for various skin conditions and are being developed to have fewer side effects.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
8 citations
,
July 2020 in “Dermatologic Therapy” Tofacitinib may effectively treat folliculitis decalvans.
8 citations
,
August 2023 in “Lasers in Surgery and Medicine” Concurrent laser and isotretinoin treatment improves acne scars more than delayed treatment.
12 citations
,
July 2012 in “Journal of cutaneous medicine and surgery” Adalimumab was safe but mostly ineffective for severe alopecia areata.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
159 citations
,
July 2014 in “Molecular pharmaceutics” New micelle nanocarriers deliver Tacrolimus more effectively to skin layers for psoriasis treatment than the current Protopic ointment.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
July 2022 in “Journal of Cosmetic Dermatology” Isotretinoin with tacrolimus may be more effective short-term for treating frontal fibrosing alopecia than finasteride with tacrolimus.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
11 citations
,
April 2015 in “International Journal of Cosmetic Science” Adenosine helps grow thicker hair in Japanese men with hair loss.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
February 2025 in “Indian Dermatology Online Journal” Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
13 citations
,
February 2020 in “Journal of the American Academy of Dermatology” Microneedling and oral tranexamic acid both improve facial melasma, but microneedling shows more sustained benefits.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.